Literature DB >> 3310650

Immunophenotyping of non-Hodgkin's lymphoma. Lack of correlation between immunophenotype and cell morphology.

H J Schuurman1, J van Baarlen, W Huppes, B W Lam, L F Verdonck, J A van Unnik.   

Abstract

The establishment of Clusters of Differentiation for T- and B-lymphoid cells during International Workshops on Human Leukocyte Differentiation Antigens prompted the authors to evaluate the immunophenotypes in 160 cases of non-Hodgkin's lymphoma (NHL). In this group, 130 were of B-lymphocyte lineage (117 by monotypic immunoglobulin expression), and 30 of T-cell lineage. In the B-NHL series the expression of immunoglobulin isotypes, B-cell maturation/differentiation antigens of CD9, CD10, CD19-24, CD37, and CD38 (OKT10), HLA-DR and peanut agglutinin binding showed no significant relationship with histopathologic diagnosis as defined by the Kiel classification. Of the T-cell markers, CD5, CD6, and CD7 showed lineage promiscuity by their presence on some B-NHL. Conversely, the authors grouped the cases according to phenotypes (either CD antigens or immunoglobulin isotypes) which occur in distinct stages of (physiologic) B-cell maturation/differentiation. Eighty-six of the 130 cases could be fitted according to CD phenotype expression. This approach did not yield a significant relationship between phenotype and individual histopathologic categories either. The staging by CD phenotype and by immunoglobulin isotype yielded different results in this respect. Most B-NHL had an intermediate stage of B-cell maturation/differentiation. In the T-NHL series most cases showed a phenotype (CD1-CD8, CD38, TdT, and peanut agglutinin binding capacity) compatible with mature T-lymphocyte characteristics. The exceptions were lymphoblastic convoluted lymphomas, which exhibited an immature immunophenotype. It is concluded that NHL in distinct histopathologic categories are heterogeneous in immunologic phenotypes, and that the immunophenotype of lymphoma cells has no evident association with that of their presumed counterparts in physiologic cell maturation/differentiation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3310650      PMCID: PMC1899688     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  32 in total

1.  CYTOCHEMICAL DEMONSTRATION OF PEROXIDASE ACTIVITY WITH 3-AMINO-9-ETHYLCARBAZOLE.

Authors:  R C GRAHAM; U LUNDHOLM; M J KARNOVSKY
Journal:  J Histochem Cytochem       Date:  1965-02       Impact factor: 2.479

2.  T-cell maturation in the human thymus and tonsil: peanut agglutinin binding T lymphocytes in thymus and tonsil differ in maturation stage.

Authors:  H J Schuurman; P Brekelmans; T Daemen; R Broekhuizen; L Kater
Journal:  Clin Immunol Immunopathol       Date:  1983-11

Review 3.  T cell subpopulations, monoclonal antibodies and their therapeutic applications.

Authors:  G Janossy; H G Prentice
Journal:  Clin Haematol       Date:  1982-10

Review 4.  The normal and malignant germinal centre.

Authors:  H Stein; J Gerdes; D Y Mason
Journal:  Clin Haematol       Date:  1982-10

5.  Immunologic phenotypes of diffuse, aggressive, non-Hodgkin's lymphomas. Correlation with clinical features.

Authors:  J Cossman; E S Jaffe; R I Fisher
Journal:  Cancer       Date:  1984-10-01       Impact factor: 6.860

6.  The immunologic characterization of 95 nodal and extranodal diffuse large cell lymphomas in 89 patients.

Authors:  R S Doggett; G S Wood; S Horning; R Levy; R F Dorfman; J Bindl; R A Warnke
Journal:  Am J Pathol       Date:  1984-05       Impact factor: 4.307

7.  Human T-cell malignancies: Correlative clinical, histopathologic, immunologic, and cytochemical analysis of 23 cases.

Authors:  D M Knowles; J P Halper
Journal:  Am J Pathol       Date:  1982-02       Impact factor: 4.307

8.  A monoclonal antibody useful for the differential diagnosis between malignant lymphoma and nonhematopoietic neoplasms.

Authors:  H Battifora; I S Trowbridge
Journal:  Cancer       Date:  1983-03-01       Impact factor: 6.860

9.  Diagnosis of human lymphoma with monoclonal antileukocyte antibodies.

Authors:  R A Warnke; K C Gatter; B Falini; P Hildreth; R E Woolston; K Pulford; J L Cordell; B Cohen; C De Wolf-Peeters; D Y Mason
Journal:  N Engl J Med       Date:  1983-11-24       Impact factor: 91.245

10.  Low-grade lymphomas. Expression of developmentally regulated B-cell antigens.

Authors:  J Cossman; L M Neckers; S Hsu; D Longo; E S Jaffe
Journal:  Am J Pathol       Date:  1984-04       Impact factor: 4.307

View more
  13 in total

1.  A novel monoclonal antibody (OPD4) recognizing a helper/inducer T cell subset. Its application to paraffin-embedded tissues.

Authors:  T Yoshino; H Mukuzono; H Aoki; K Takahashi; T Takeuchi; I Kubonishi; Y Ohtsuki; M Motoi; T Akagi
Journal:  Am J Pathol       Date:  1989-06       Impact factor: 4.307

2.  Nuclear antigens in neoplastic lymphocytes of B cell and T cell non-Hodgkin's lymphomas.

Authors:  I Dardick; R Hall; D J Bailey; M Stratis; D L Brown; N Chaly
Journal:  Am J Pathol       Date:  1989-01       Impact factor: 4.307

3.  Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients.

Authors:  Ajay K Gopal; Stefano R Tarantolo; Naresh Bellam; Damian J Green; Melissa Griffin; Tatyana Feldman; Anthony R Mato; Amy J Eisenfeld; Scott C Stromatt; Andre Goy
Journal:  Invest New Drugs       Date:  2014-06-15       Impact factor: 3.850

4.  A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies.

Authors:  Karl-Heinz Heider; Kerstin Kiefer; Thorsten Zenz; Matthias Volden; Stephan Stilgenbauer; Elinborg Ostermann; Anke Baum; Herbert Lamche; Zaruhi Küpcü; Alexander Jacobi; Steffen Müller; Ulrich Hirt; Günther R Adolf; Eric Borges
Journal:  Blood       Date:  2011-07-27       Impact factor: 22.113

5.  Expression of RNA and antigens of human immunodeficiency virus type-1 (HIV-1) in lymph nodes from HIV-1 infected individuals.

Authors:  H J Schuurman; W J Krone; R Broekhuizen; J Goudsmit
Journal:  Am J Pathol       Date:  1988-12       Impact factor: 4.307

6.  Clinicopathologic significance of loss of CD19 expression in diffuse large B-cell lymphoma.

Authors:  Miho Kimura; Motoko Yamaguchi; Shigeo Nakamura; Hiroshi Imai; Satoshi Ueno; Shoko Ogawa; Kana Miyazaki; Kouji Oka; Toshiyuki Ohno; Kenkichi Kita; Tohru Kobayashi; Hiroshi Shiku
Journal:  Int J Hematol       Date:  2007-01       Impact factor: 2.490

7.  Proteoglycan-targeted antibodies as markers on non-Hodgkin lymphoma xenografts.

Authors:  L Kopper; A Bankfalvi; R Mihalik; T T Glant; J Timar
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

8.  Immunophenotyping of non-Hodgkin's lymphoma. Correlation with relapse-free survival.

Authors:  H J Schuurman; W Huppes; L F Verdonck; J Van Baarlen; J A Van Unnik
Journal:  Am J Pathol       Date:  1988-04       Impact factor: 4.307

9.  Differential cross-reactivity of monoclonal antibody OPD4 (anti-CD45RO) in macaques.

Authors:  Xiaolei Wang; Bapi Pahar; Terri Rasmussen; Xavier Alvarez; Jason Dufour; Kelsi Rasmussen; Andrew A Lackner; Ronald S Veazey
Journal:  Dev Comp Immunol       Date:  2008-01-28       Impact factor: 3.636

10.  The leukocyte semaphorin CD100 is expressed in most T-cell, but few B-cell, non-Hodgkin's lymphomas.

Authors:  D M Dorfman; A Shahsafaei; L M Nadler; G J Freeman
Journal:  Am J Pathol       Date:  1998-07       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.